The FDA approved it........it's been studied for a long time.........The CDC is always skeptical.......they don't like saying anything without a lot of experiments..............but when there is no time you must do what you have to do.
The REAL STORY HERE......is that the Dems and their Media got their panties in a wad because Trump was praising it...................
So IGNORANT are these TDS clowns that several Governors BANNED IT until they went OH SHIT OUR PEOPLE ARE DYING..............and lifted the Ban.
The Drug is WORKING.........It is fairly Cheap............and it has been used for a long long time now.
Is it working? I've still only seen the 2 small studies to indicate it works, and 1 small study that indicated it does not. I've read that it is being used in various places, but is there any actual data about its effectiveness in those places? Everything seems anecdotal at best, more often just rumor. I may not know the right places to find the information, though.
Many states are using it now..........I've heard stories on this board posting it is working........if it didn't work we'd hear the talking heads blaring it all over the news............
The Media being silent on it is probably a very good indicator it works.
Your moron leader is on TV now bullshitting about these drugs.
So............From what I've heard they are working ........
Nobody in this world knows if they will work or if they won’t work. You’ve heard rumors.
They are doing the studies .......not in a lab..........but on patients who don't have much choice.
BTW.........Why the hell are you so dang UPSET about these DRUGS........I'll tell you why....TDS...........
While it's not the same Drug..........UAB has been studying these drugs before anyone even knew Trump was running for office.
This novel coronavirus strain wasn't seen until recently. Obviously no one was studying the effects of any drugs on the SARS-CoV-2 virus before Trump ran for office.
Baloney.
It is another strain and they have been studying it since 2003
And why they have treatment options so quick.
An antibody recovered from a survivor of the SARS epidemic in the early 2000s has revealed a potential vulnerability of the new coronavirus at the root of COVID-19, according to a study from scientists at Scripps Research.
www.eurekalert.org
SARS-CoV, which causes SARS, originated in horseshoe bats, but jumped to humans in South China in 2002, eventually infecting more than 8,000 people and killing almost 800 before it was quelled by lockdowns, quarantines and other measures.
SARS-CoV-2, a closely related coronavirus that causes COVID-19, first emerged in the Chinese city of Wuhan in late 2019. Much more infectious than its viral cousin, it has led to a pandemic, causing far more cases of illness and fatalities than SARS. The development of a vaccine or even an effective treatment could significantly ameliorate the crisis.
The Wilson lab is known for its pioneering structural studies of antibodies bound to viruses including HIV and influenza. These studies have been used to inform designs of vaccines and antibody drugs, as well as other therapeutics. Along with hundreds of other labs around the world, Wilson's team is now focused on SARS-CoV-2.
"Our ultimate goal here is to obtain structural information on antibodies and their binding sites, and use that to guide SARS-CoV-2 vaccine design, just as our lab has done with influenza and HIV," says the study's co-first author Nicholas Wu, PhD, a postdoctoral research associate in the Wilson lab.
The new study centers on an anti-SARS-CoV antibody called CR3022 that was originally isolated in 2006 by the pharmaceutical company Crucell Holland B.V. in the Netherlands. A report from Chinese scientists earlier this year indicated that CR3022 cross-reacts against SARS-CoV-2. Wilson's team used their structural mapping expertise to determine how the antibody binds to SARS-CoV-2.
A key finding is that the antibody's binding site is highly similar between the two coronaviruses--differing by just four protein building blocks called amino-acids. That high degree of similarity implies that the site has an important function that would be lost if it mutated significantly.
theintercept.com
